ISSN: 1859 - 2872
Efficacy of ustekinumab for treatment of moderate - to - severe plaque psoriasis at 108 Military Central Hospital
Main Article Content
Keywords
Abstract
Objective: To assess the efficacy of ustekinumab in patient with moderate-to-severe plaque psoriasis. Subject and method: A retrospective study; 14 patients (male or female) aged ≥ 18 years with moderate-to-severe chronic plaque psoriasis; to receive subcutaneous injections of ustekinumab 45mg at week 0, 4, 16 and 28. Evaluate efficacy at week 4, 16, 28 included the proportion of patients achieving at least 75%, 90%, 100% improvement from baseline in Psoriasis Area and Severity Index (PASI 75, PASI 90, PASI 100), change from baseline in Dermatology Life Quality Index (DLQI). Result: At week 16, the proportion of patients achieving PASI 75 was 50%, PASI 90 was 28.6%, 35.7% of patients achieved DLQI 0/1. Efficacy was maintained through week 28 in ustekinumab - treated patients. Serious adverse drug reaction observed was 0%. At week 28, 1 patient with < 50% improvement in Psoriasis Area and Severity Index (PASI) discontinued ustekinumab. Conclusion: Ustekinumab was efficacious and generally
well-tolerated in patients with moderate-to-severe plaque-type psoriasis through 28 weeks.
Article Details
References
2. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K; PHOENIX 2 study investigators (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis:
52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371(9625): 1675-1684.
3. Tsai TF, Ho JC, Song M, Szapary P, Guzzo C, Shen YK, Li S, Kim KJ, Kim TY, Choi JH, Youn JI; PEARL Investigators (2011) Efficacy and safety of ustekinumab for the treatment of moderate-
to-severe psoriasis: A phase III, randomized,
placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci 63(3): 154-163.
4. Gil-Sierra MD, Ríos-Sánchez E and Briceño-Casado, MDP (2020) Use of ustekinumab after other biological therapies in moderate-severe psoriasis: Real long-term data. Farm Hosp 44(5): 218-221.
5. Igarashi A, Kato T, Kato M, Song M, Nakagawa H; Japanese Ustekinumab Study Group (2012) Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial. J Dermatol 39(3): 242-252.
6. Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y, Dooley LT, Lebwohl M; CNTO 1275 Psoriasis Study Group (2007) A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 356(6):
580-592.
7. Lee HY, Woo CH and Haw S (2017) Paradoxical flare of psoriasis after ustekinumab therapy.
Ann Dermatol 29(6): 794-795.
8. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB; PHOENIX 1 study investigators (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis:
76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371(9625): 1665-1674.
9. Zhu X, Zheng M, Song M, Shen YK, Chan D, Szapary PO, Wang B; LOTUS Investigators (2013) Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: Results from a phase 3 clinical trial (LOTUS). J Drugs Dermatol 12(2): 166-74.
Article Sidebar
